Related Experiment Videos
Antibiotic associated diarrhoea and enterocolitis
1Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Abstract:
C. difficile is the major aetiological agent of AAD and PMC and results from overgrowth of C. difficile already present endogenously or of newly acquired exogenous organisms after suppression of competing gut flora. C. difficile produces two kinds of toxins A and B. These toxins attack the colonic mucosa which becomes necrotic with the formation in fulminating cases of an exudative pseudomembrane. Toxigenic and non-toxigenic strains of C. difficile may be present together in an individual suffering from AAD. There is substantial variation among strains with respect to the quantity of lethal toxin produced. There are several strategies available for the investigation of C. difficile associated disease. Detection of toxins by neutralization with C. sordelli antitoxin is an easy, simple and sensitive method. Methods to deal effectively with silent carriers are not known because the routine administration of antibiotic treatment in an attempt to eradicate the carrier state would in fact boomerang by promoting C. difficile associated enteric disease rather than eliminating C. difficile.
Insights
Clostridioides difficile causes antibiotic-associated diarrhea (AAD) and pseudomembranous colitis (PMC) through toxin production. Effective strategies for managing silent carriers of this bacterium remain unknown.
Area of Science:
- Microbiology
- Gastroenterology
- Infectious Diseases
Background:
- Clostridioides difficile is a primary cause of antibiotic-associated diarrhea (AAD) and pseudomembranous colitis (PMC).
- Disease results from the overgrowth of endogenous or exogenous C. difficile strains following disruption of normal gut flora.
- C. difficile produces toxins A and B, which damage the colonic mucosa, leading to necrosis and pseudomembrane formation in severe cases.
Purpose of the Study:
- To review the etiology and investigation strategies for C. difficile-associated diseases.
- To highlight the challenges in managing asymptomatic carriers of C. difficile.
Main Methods:
- Review of existing literature on C. difficile pathogenesis and diagnostics.
- Discussion of toxin detection methods, including neutralization assays with C. sordellii antitoxin.
- Analysis of treatment strategies and their limitations, particularly for carrier states.
Main Results:
- C. difficile toxins A and B are key virulence factors causing mucosal damage.
- Toxin neutralization assays offer a sensitive and straightforward method for C. difficile toxin detection.
- Current antibiotic treatments may inadvertently promote C. difficile-associated enteric disease in carriers.
Conclusions:
- C. difficile infection presents a significant clinical challenge due to its varied presentation and toxin production.
- Simple and sensitive diagnostic methods for C. difficile toxins are available.
- Effective interventions for asymptomatic C. difficile carriers are lacking, and antibiotic use can be counterproductive.